Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients
NCT04502680
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Triple Negative Breast Cancer
Interventions
DRUG:
Eribulin Mesylate
Sponsor
The First Affiliated Hospital with Nanjing Medical University